High-Risk Ventures: What Are They Called?

Risk is an important aspect of investing. While there is no perfect definition or measurement of risk, it is generally understood as the possibility or probability of an asset experiencing a permanent loss in value or underperformance relative to expectations. High-risk investments, therefore, entail a large chance of loss of capital or underperformance, or a high likelihood of a significant loss. These investments may offer the potential for higher returns, but they also put your money at greater risk. Examples of high-risk investments include investing in options, initial public offerings, foreign emerging markets, and cryptocurrency.

Cryptoassets

As a high-risk investment, cryptoassets may offer the chance of higher returns than other investments, but they put your money at higher risk. This means that if the investment performs well, you may see high returns. However, if it performs poorly, you could lose all of your investment. The chance of things going badly is higher with cryptoassets, and there is no guarantee of high returns.

Additionally, cryptoassets may be more challenging to access and have lower liquidity than mainstream investments. This means that if you need to withdraw your money, it may not be as easy, and you may have to pay fees or penalties.

In summary, cryptoassets are high-risk investments that offer the potential for high returns but also carry the significant risk of losing your entire investment. They are suitable only for experienced investors who understand the risks involved.

Mini-bonds

In addition, mini-bond investors are unlikely to be protected by the Financial Services Compensation Scheme (FSCS) if something goes wrong. This means that if the issuer fails or goes out of business, investors could lose all their money.

The high-risk nature of mini-bonds is reflected in the high returns they offer. However, there is no guarantee that these returns will be achieved, and investors must be prepared to lose all their money.

Due to the risks involved, the Financial Conduct Authority (FCA) has banned the promotion of speculative mini-bonds to consumers unless they are sophisticated investors or have a high net worth. When promoted to these investors, issuers must clearly state the risk of losing all investments and provide clear information on costs and charges.

Contracts for Difference (CFDs)

In a CFD, an investor bets on the future value of an asset without actually owning or taking physical delivery of it. The investor agrees to exchange the difference in the value of the asset between the time the contract opens and closes. For example, if a trader buys a CFD for a share, they are betting that the share price will increase. If the share price does indeed increase, the trader will offer their CFD for sale. The net difference between the purchase price and the sale price is then settled through the investor's brokerage account.

CFDs are popular in over-the-counter exchanges around the world and are allowed in many countries, including the United Kingdom, Australia, Germany, and Canada. However, they are not permitted in the United States due to their high risk and lack of regulation.

There are several advantages to trading CFDs, including lower margin requirements, easy access to global markets, no shorting or day trading rules, and minimal fees. Additionally, CFDs provide access to underlying assets at a lower cost than buying them outright.

However, there are also significant risks associated with CFDs. The CFD industry is not highly regulated, and there are liquidity risks and margin requirements that investors need to maintain. Leverage risks in CFD trading can expose investors to greater potential profits but also greater potential losses. If an investor cannot cover reductions in values, their provider may close their position, resulting in a loss.

Overall, Contracts for Difference (CFDs) are a potentially high-risk investment option that offers both opportunities for profit and significant risks of loss.

Biotechnology stocks

Investing in the biotech industry is notoriously risky. Biotechnology stocks are high-risk, high-reward stocks. Many biotech companies are working to develop world-changing drugs to address billion-dollar markets. The fate of these volatile stocks is often tied to study data and approval decisions from drug regulators such as the U.S. Food and Drug Administration (FDA).

However, biotechnology stocks can also offer significant long-term growth potential. These companies drive medical innovation and develop therapies that can revolutionise healthcare. For example, in 2020, the industry was thrust into the pandemic limelight as Pfizer and BioNTech, along with Moderna and Johnson & Johnson, launched a trio of Covid-19 vaccines.

Some of the biggest biotech stocks in terms of market cap include Amgen, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, and Gilead Sciences. Vertex Pharmaceuticals, for instance, specialises in developing therapies to treat cystic fibrosis and currently leads the cystic fibrosis drug market.

Overall, while biotechnology stocks offer the potential for high returns, they also carry a significant risk of loss. Investors considering this sector should carefully evaluate the risks and ensure they have the appropriate risk tolerance and investment horizon.

Initial Public Offerings (IPOs)

IPOs are often used by companies to raise significant capital to fund new growth, pay off debt, or pay early investors. For investors, IPOs can be an opportunity to get in on the ground floor of a company's public trading. However, they are a risky investment because there is a high degree of uncertainty about the company's future performance and whether its management will be able to deliver on its promises.

The IPO process is lengthy and involves a company working with underwriters (usually investment banks) to prepare and file the necessary paperwork, create a prospectus, market the share issuance, and more. The underwriters play a crucial role in determining the IPO price and the number of shares offered.

While IPOs can offer high rewards, there is also a significant chance of losing money. The majority of IPOs fail to generate significant returns or any returns at all. Additionally, there are costs and disadvantages associated with IPOs, such as legal, accounting, and marketing fees, as well as the requirement to disclose sensitive business information.

Overall, IPOs are a high-risk investment strategy that should only be considered by experienced investors who are prepared to lose their investment.

Frequently asked questions